Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

567
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
567
Standards of Care II01:19

Standards of Care II

942
Nurses bear specific legal responsibilities under several federal statutes, including:
942
Standards of Care I01:22

Standards of Care I

974
Federal statutes profoundly impact nursing practice, providing critical guidelines to ensure patient care is equitable, accessible, and of the highest quality. The following laws address distinct aspects of healthcare provision and patient rights:
974
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

299
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
299
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Cancer Therapies02:49

Cancer Therapies

9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measuring Equitable Care Delivery: Insights From the Health Equity Report Card (HERC) Pilot in Academic Cancer Centers.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.

Nature medicine·2026
Same author

Feasibility and Safety of High-Dose Proton Re-Irradiation in Recurrent Pediatric Central Nervous System Tumors: A Single-Institution Retrospective Study.

Pediatric blood & cancer·2026
Same author

Nationwide Mammographic Screening Among a Large Population of Underserved Subgroups.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Primary Care and Oncology Collaboration to Improve Patient Outcomes.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.

Blood·2026

Related Experiment Video

Updated: Dec 12, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

557

NCCN Guidelines Insights: Survivorship, Version 2.2020.

Crystal S Denlinger1, Tara Sanft2, Javid J Moslehi3

  • 1Fox Chase Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN
|August 7, 2020
PubMed
Summary

The National Comprehensive Cancer Network (NCCN) updated survivorship guidelines in 2020 to improve care for adult cancer survivors. Key changes focus on cardiovascular disease risk and screening for new primary cancers.

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.6K

Related Experiment Videos

Last Updated: Dec 12, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

557
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.6K

Area of Science:

  • Oncology
  • Public Health
  • Clinical Practice Guidelines

Background:

  • Adult cancer survivors face long-term health consequences and increased risks.
  • Effective survivorship care requires coordinated efforts across healthcare settings.
  • Primary care physicians play a crucial role in managing survivor health.

Purpose of the Study:

  • To summarize 2020 updates to the NCCN Guidelines for Survivorship.
  • To highlight changes in cardiovascular disease risk assessment for survivors.
  • To detail new recommendations for screening subsequent primary malignancies.

Main Methods:

  • Review and synthesis of the NCCN Guidelines for Survivorship.
  • Focus on additions and modifications made in the 2020 version.
  • Analysis of recommendations for primary care and specialists.

Main Results:

  • Updated recommendations for cardiovascular disease risk assessment in cancer survivors.
  • New screening guidelines for identifying subsequent primary malignancies.
  • Emphasis on promoting healthy lifestyle factors like physical activity and weight management.

Conclusions:

  • The 2020 NCCN Guidelines provide essential updates for optimizing cancer survivorship care.
  • These guidelines aim to reduce long-term morbidity and improve quality of life for survivors.
  • Enhanced screening and risk assessment are critical for addressing survivor health needs.